Uli C. Broedl

Boehringer Ingelheim (United States) — United States

Medicine · Health Sciences

62h-index32.0kcitations146works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Diabetes Treatment and Management(93), Pancreatic function and diabetes(66), Metabolism, Diabetes, and Cancer(41), Diabetes Management and Research(38), Chronic Kidney Disease and Diabetes(11)

Publications146 total

Framework of the strengths and challenges of clinically integrated trials: An expert panel report
American Heart Journal·2024· 1 citedOpen Access
Inclusion and diversity in clinical trials: Actionable steps to drive lasting change
Contemporary Clinical Trials·2022· 157 citedOpen Access
Leveraging Blockchain Technology for Informed Consent Process and Patient Engagement in a Clinical Trial Pilot
Blockchain in Healthcare Today·2021· 10 citedOpen Access
Correction to: The role of machine learning in clinical research: transforming the future of evidence generation
Trials·2021· 25 citedOpen Access
The role of machine learning in clinical research: transforming the future of evidence generation
Trials·2021· 269 citedOpen Access
Can the cardiovascular risk reductions observed with empagliflozin in the EMPA‐REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?
Diabetes Obesity and Metabolism·2020· 15 cited
Author response for "Can the Cardiovascular Risk Reductions Observed with Empagliflozin in the EMPA‐REG OUTCOME Trial be Explained by Concomitant Changes Seen in Conventional Cardiovascular Risk Factor Levels?"
2020
Predictions for Blockchain in 2020
Blockchain in Healthcare Today·2020· 1 citedOpen Access
Data Sharing? The Case for Blockchain at the Global Convergence of Healthcare, Life sciences, and Consumer Markets
SHILAP Revista de lepidopterología·2018Open Access
Blockchain Technology in Clinical Trials
SHILAP Revista de lepidopterología·2018· 2 citedOpen Access
Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial
Journal of the American Society of Nephrology·2018· 194 citedOpen Access
Correction to: Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study
Diabetes Therapy·2018· 1 citedOpen Access
Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk
Cardiovascular Diabetology·2018· 82 citedOpen Access
Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease
Journal of the American College of Cardiology·2018· 39 cited
Are the Cardiovascular (CV) Risk Reductions Seen with Empagliflozin in the EMPA-REG OUTCOME Trial Explained by Conventional CV Risk Factors?
Canadian Journal of Diabetes·2017· 1 cited
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
Circulation·2017· 463 citedOpen Access
Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin
Kidney International·2017· 240 citedOpen Access
Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?
Diabetes Care·2017· 65 cited
The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus
Journal of the American Society of Hypertension·2017· 94 cited
Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
Stroke·2017· 133 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Hans J. Woerle(20), Odd Erik Johansen(15), Christoph Wanner(10), Bernard Zinman(9), Hans J. Woerle(9), Michaela Mattheus(8), Silvio E. Inzucchi(8), Stefan Hantel(7), Maximilian von Eynatten(7), Hans‐Juergen Woerle(7), Afshin Salsali(7), John M. Lachin(6), David Fitchett(6), David Z.I. Cherney(6), Nima Soleymanlou(6), Klaus G. Parhofer(6), Gabriel Kim(6), Bruce A. Perkins(5), Michael Lehrke(5), Søren S. Lund(5)